Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 2021-08-25
Type
Journal Article
Author
Jerald Sadoff
Author
Mathieu Le Gars
Author
Georgi Shukarev
Author
Dirk Heerwegh
Author
Carla Truyers
Author
Anne M. de Groot
Author
Jeroen Stoop
Author
Sarah Tete
Author
Wim Van Damme
Author
Isabel Leroux-Roels
Author
Pieter-Jan Berghmans
Author
Murray Kimmel
Author
Pierre Van Damme
Author
Jan de Hoon
Author
William Smith
Author
Kathryn E. Stephenson
Author
Stephen C. De Rosa
Author
Kristen W. Cohen
Author
M. Juliana McElrath
Author
Emmanuel Cormier
Author
Gert Scheper
Author
Dan H. Barouch
Author
Jenny Hendriks
Author
Frank Struyf
Author
Macaya Douoguih
Author
Johan Van Hoof
Author
Hanneke Schuitemaker
URL
https://www.nejm.org/doi/10.1056/NEJMoa2034201
Rights
Copyright © 2021 Massachusetts Medical Society. All rights reserved.
Volume
384
Pages
1824-1835
Publication
New England Journal of Medicine
Date
13/01/2021
Loc. in Archive
world
Extra
Publisher: Massachusetts Medical Society
DOI
10.1056/NEJMoa2034201
Library Catalog
www.nejm.org
Language
en
Abstract
Original Article from The New England Journal of Medicine — Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine